Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Pain Reduction by Dehydrated Human Amnion/chorion Membrane Allograft in Non-diabetic Leg Ulcers Might be an Early Indicator of Good Response: A Case Series
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4598092
Author(s) Mueller, Simon M.; Navarini, Alexander A.; Itin, Peter; Schwegler, Simon; Laeuchli, Severin; Goldust, Mohamad; Ivanova, Katja
Author(s) at UniBasel Navarini, Alexander
Year 2020
Title Pain Reduction by Dehydrated Human Amnion/chorion Membrane Allograft in Non-diabetic Leg Ulcers Might be an Early Indicator of Good Response: A Case Series
Journal Dermatologic Therapy
Volume 33
Number 4
Pages / Article-Number e13587
Abstract Dehydrated human amnion/chorion membrane allograft (dHACM) derived from placenta is increasingly used for skin and soft tissue repair in several medical specialties. Promising effects of dHACM were also reported in chronic venous and diabetic leg ulcers. However, dHACM is cost-intensive and its effect on chronic leg ulcers of other etiologies and pain reduction is unknown. Clinical predictors of a favorable response to dHACM during the early treatment period could help to limit unnecessary costs. In our case series with six patients suffering from chronic lower leg ulcers of various etiology, the effect of dHACM once per week on reduction of pain and wound size during a 5-week period was examined. dHACM resulted in effective pain reduction and improved wound healing in three patients with chronic leg ulcers due to calciphylaxis, chronic venous disease and reactive angioendotheliomatosis. Pain reduction after 1 to 2 applications of dHACM predicted a favorable healing response. Hence, our observation indicates that assessment of pain 3 weeks after initiation of dHACM may be a clinical predictor to justify dis-/continuation of dHACM and thereby may help to limit costs.
Publisher Wiley
ISSN/ISBN 1396-0296 ; 1529-8019
edoc-URL https://edoc.unibas.ch/76701/
Full Text on edoc No
Digital Object Identifier DOI 10.1111/dth.13587
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/32410269
 
   

MCSS v5.8 PRO. 0.361 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
20/04/2024